Clinical Trial Results:
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.
Summary
|
|
EudraCT number |
2004-004061-15 |
Trial protocol |
BE IE ES IT SK CZ SI BG PL |
Global end of trial date |
15 Dec 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Oct 2016
|
First version publication date |
29 Oct 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SPD422-403
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00202644 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Shire Pharmaceutical Development Ltd
|
||
Sponsor organisation address |
Hampshire International Business Park, Chineham, Basingstoke, Hampshire, United Kingdom, RG24 8EP
|
||
Public contact |
Study Physician, Shire, +1 866-842-5335,
|
||
Scientific contact |
Study Physician, Shire, +1 866-842-5335,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
15 Dec 2015
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Dec 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of this study was to compare the safety of anagrelide and hydroxyurea in short and long term usage of up to three years with particular reference to cardiovascular safety (as assessed by echocardiography).
|
||
Protection of trial subjects |
This study was conducted in accordance with International Conference on Harmonisation (ICH) of Good Clinical Practice (GCP), the principles of the Declaration of Helsinki, and other applicable local ethical and legal requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
13 Jan 2006
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
3 Years | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 1
|
||
Country: Number of subjects enrolled |
Bulgaria: 34
|
||
Country: Number of subjects enrolled |
France: 14
|
||
Country: Number of subjects enrolled |
Hungary: 21
|
||
Country: Number of subjects enrolled |
Ireland: 1
|
||
Country: Number of subjects enrolled |
Poland: 39
|
||
Country: Number of subjects enrolled |
Portugal: 9
|
||
Country: Number of subjects enrolled |
Serbia: 18
|
||
Country: Number of subjects enrolled |
Slovenia: 2
|
||
Country: Number of subjects enrolled |
Spain: 7
|
||
Worldwide total number of subjects |
146
|
||
EEA total number of subjects |
128
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
111
|
||
From 65 to 84 years |
35
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||
Recruitment details |
- | |||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||
Screening details |
A total of 183 subjects were screened, 149 subjects were randomized at 29 sites across 10 countries. Four (4) subjects randomized but withdrawn prior to treatment and 1 subject not randomized but treated. | |||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Anagrelide | |||||||||||||||||||||||||||
Arm description |
Subjects received Anagrelide hydrochloride 1.0 milligram (mg) per day administered orally as 0.5 mg capsule twice daily (bid) for 1 week. Then the dose was titrated such that the total daily dose is incremented by no more than 0.5 mg in any 1 week and the recommended maximum single dose could not exceed 2.5 mg as required depending on platelet reduction versus adverse event profile. Total daily dosage was not exceed 10 mg. Subjects followed for up to 3 years. | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Anagrelide
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Subjects received Anagrelide hydrochloride 1.0 milligram (mg) per day administered orally as 0.5 mg capsule twice daily (bid) for 1 week. Then the dose was titrated such that the total daily dose is incremented by no more than 0.5 mg in any 1 week and the recommended maximum single dose could not exceed 2.5 mg as required depending on platelet reduction versus adverse event profile. Total daily dosage was not exceed 10 mg. Subjects followed for up to 3 years.
|
|||||||||||||||||||||||||||
Arm title
|
Hydroxyurea | |||||||||||||||||||||||||||
Arm description |
Subjects received Hydroxyurea as 1000 mg per day administered orally as 500 mg capsule twice daily and dose titrated to effect to achieve a response. Subjects followed for up to 3 years. | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Hydroxyurea
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Subjects received Hydroxyurea as 1000 mg per day administered orally as 500 mg capsule twice daily and dose titrated to effect to achieve a response. Subjects followed for up to 3 years.
|
|||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Anagrelide
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Anagrelide hydrochloride 1.0 milligram (mg) per day administered orally as 0.5 mg capsule twice daily (bid) for 1 week. Then the dose was titrated such that the total daily dose is incremented by no more than 0.5 mg in any 1 week and the recommended maximum single dose could not exceed 2.5 mg as required depending on platelet reduction versus adverse event profile. Total daily dosage was not exceed 10 mg. Subjects followed for up to 3 years. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Hydroxyurea
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Hydroxyurea as 1000 mg per day administered orally as 500 mg capsule twice daily and dose titrated to effect to achieve a response. Subjects followed for up to 3 years. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Anagrelide
|
||
Reporting group description |
Subjects received Anagrelide hydrochloride 1.0 milligram (mg) per day administered orally as 0.5 mg capsule twice daily (bid) for 1 week. Then the dose was titrated such that the total daily dose is incremented by no more than 0.5 mg in any 1 week and the recommended maximum single dose could not exceed 2.5 mg as required depending on platelet reduction versus adverse event profile. Total daily dosage was not exceed 10 mg. Subjects followed for up to 3 years. | ||
Reporting group title |
Hydroxyurea
|
||
Reporting group description |
Subjects received Hydroxyurea as 1000 mg per day administered orally as 500 mg capsule twice daily and dose titrated to effect to achieve a response. Subjects followed for up to 3 years. |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time [1] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
The LVEF was considered a sufficiently sensitive measure to evaluate any changes in cardiac function. The Full Analysis Set (FAS) population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded. Here, n = Number of subjects analyzed for specified category at the specified time points in each arm respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and Month 1, 2, 3, 6, 9, 12, 18, 24, 30 and 36
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No inferential statistical analysis was planned for this end-point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Platelet Count at Month 6 | ||||||||||||
End point description |
Platelet count was evaluated. The FAS population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded. Here, N = Number of subjects analyzed in each arm for this endpoint.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Month 6
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Anagrelide Vs Hydroxyurea | ||||||||||||
Comparison groups |
Hydroxyurea v Anagrelide
|
||||||||||||
Number of subjects included in analysis |
118
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority [2] | ||||||||||||
Method |
|||||||||||||
Parameter type |
Least Square Mean | ||||||||||||
Point estimate |
-100.5
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-179.42 | ||||||||||||
upper limit |
-21.49 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
39.93
|
||||||||||||
Notes [2] - Non-inferiority of anagrelide could be concluded if lower limit of 95% Confidence Interval for the difference between treatment groups (Hydroxyurea - Anagrelide) was > -100 x 10^9/Liter. |
|
|||||||||||||||||||
End point title |
Change From Baseline in Platelet Counts at Month 3 and 36 | ||||||||||||||||||
End point description |
Platelet count was evaluated throughout the study. The FAS population included all randomized participants who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded with last observation carried forward (LOCF). Here, n=number of subjects analysed for specified category at specified time points in each arm respectively.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline and Month 3 and 36
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Anagrelide Vs Hydroxyurea: Month 3 | ||||||||||||||||||
Comparison groups |
Anagrelide v Hydroxyurea
|
||||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
non-inferiority [3] | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Least Square Mean | ||||||||||||||||||
Point estimate |
-113.1
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-187.4 | ||||||||||||||||||
upper limit |
-38.83 | ||||||||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||||||||
Dispersion value |
37.56
|
||||||||||||||||||
Notes [3] - Non-inferiority of anagrelide could be concluded if lower limit of 95% Confidence Interval for the difference between treatment groups (Hydroxyurea - Anagrelide) was > -100 x 10^9/Liter. |
|||||||||||||||||||
Statistical analysis title |
Anagrelide Vs Hydroxyurea: Month 36 | ||||||||||||||||||
Comparison groups |
Anagrelide v Hydroxyurea
|
||||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
non-inferiority [4] | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Least Square Mean | ||||||||||||||||||
Point estimate |
-68.3
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-154.95 | ||||||||||||||||||
upper limit |
18.43 | ||||||||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||||||||
Dispersion value |
43.83
|
||||||||||||||||||
Notes [4] - Non-inferiority of anagrelide could be concluded if lower limit of 95% Confidence Interval for the difference between treatment groups (Hydroxyurea - Anagrelide) was > -100 x 10^9/Liter. |
|
|||||||||||||
End point title |
Percentage of Subjects With Complete Response | ||||||||||||
End point description |
A complete response was defined as a platelet count of less than (<) 400x10^9/Liter which was confirmed over 2 consecutive visits at least 28 days apart. The FAS population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline up to Month 36
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Partial Response | ||||||||||||
End point description |
A partial response is defined as a platelet count of 400-600 x 10^9/Liter and a reduction in platelet count of at least 200 x 10^9/Liter from baseline which was confirmed over 2 consecutive visits at least 28 days apart. The FAS population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline up to Month 36
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Time to Complete Response | ||||||||||||
End point description |
Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a subject did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). The FAS population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline up to Month 36
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Time to Partial Response | ||||||||||||
End point description |
Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a subject did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). The FAS population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline up to Month 36
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Subjects With Thrombotic and Haemorrhagic Events | ||||||||||||
End point description |
Thrombohaemorrhagic events are a well-known complication of the underlying essential thrombocythemia (ET) and disease progression. Events such as arterial and venous thrombosis, serious haemorrhage (including gastrointestinal haemorrhage), and death from vascular causes have been reported in subjects who received cytoreductive treatment. The FAS population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From the signing of informed consent until the last study-related visit (Month 36)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in White Blood Cell Count Over Time | |||||||||||||||||||||||||||||||||
End point description |
White blood cell count was evaluated throughout the study. The FAS population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded. Here, n = Number of subjects analyzed for specified category at the specified time points in each arm respectively.
|
|||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and Month 6, 12, 18, 24, 30 and 36
|
|||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Red Blood Cell Count Over Time | |||||||||||||||||||||||||||||||||
End point description |
Red blood cell count was evaluated throughout the study. The FAS population included all randomized subjects who received at least 1 dose of study medication and who had a pretreatment and at least 1 post baseline LVEF measurement recorded. Here, n = Number of subjects analyzed for specified category at the specified time points in each arm respectively.
|
|||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and Month 6, 12, 18, 24, 30 and 36
|
|||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the signing of informed consent until the last study-related visit (Month 36)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Hydroxyurea
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Hydroxyurea as 1000 mg per day administered orally as 500 mg capsule twice daily and dose titrated to effect to achieve a response. Subjects followed for up to 3 years. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Anagrelide
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Anagrelide hydrochloride 1.0 milligram (mg) per day administered orally as 0.5 mg capsule twice daily (bid) for 1 week. Then the dose was titrated such that the total daily dose is incremented by no more than 0.5 mg in any 1 week and the recommended maximum single dose could not exceed 2.5 mg as required depending on platelet reduction versus adverse event profile. Total daily dosage was not exceed 10 mg. Subjects followed for up to 3 years. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
16 May 2005 |
1. Details of the Medical Toxicology Unit Information Services were added to the emergency contact list. 2. Administrative changes were made to address inconsistency between synopsis and main text. 3. The requirement to formally document drug compliance in the electronic case report form (eCRF) was removed. 4. The serious adverse events (SAE) reporting requirements were clarified. |
||
03 Nov 2005 |
1. The principal investigator, project physician, and study manager were changed. 2. The exclusion criterion related to renal and hepatic impairment was updated to exclude not only subjects with severe renal or hepatic impairment but also those with moderate impairment. 3. New participating countries were added. 4. Requirements for subject identification were updated to comply with local requirements. |
||
08 Aug 2006 |
1. The contract research organization (CRO) and respective contact details were changed. 2. The emergency contact details were changed. 3. The responsible Shire Project Physician was changed. 4. Listed participating countries were deleted and recruitment expanded to other European Union (EU) territories. |
||
11 Feb 2008 |
1. Holter monitoring to diagnose cardiac symptoms which may indicate arrhythmia was added. 2. The CRO conducting and reading echocardiographs was changed. 3. The sample subject information and consent form and information for subjects requiring bone marrow biopsy or aspiration was removed from the appendix. 4. Drug accountability records were clarified. |
||
20 Apr 2009 |
1. The principal coordinating investigator was changed. 2. Shire staff contact information on Emergency Contact Information page was updated. 3. Study Design was updated to state that overall study duration was estimated to be at least 7 years. 4. Number and Source of Subjects was updated to state that 184 high-risk essential thrombocythemia (ET) subjects would be enrolled across 50 sites. 5. The cross reference was removed from the heading to after the statement diagnosis of ET. 6. The sentence “Subjects may however participate in study SPD422-403 whilst still enrolled in this study.” was removed. 7. The following sentence was added Withdrawal of Subjects: “Subjects who withdraw from the study will return to the routine clinical care of their physician. 8. The following text regarding hydroxycarbamide capsules was added to Investigational Product[s]: “There are 10 capsules per blister pack and 10 blister packs are provided in a carton.” 9. The following text was deleted in Labeling, Packaging, Storage, and Handling: “provided that the blind of the study is not compromised”. 10. Echocardiogram and Holter Monitoring to Diagnose Cardiovascular Symptoms were updated to include the name of the CRO, the central reader of the Echocardiograms and Echocardiographs. 11. The following sentence was added to Serious Adverse Event Procedures: “The reference for safety information for this study is the current Investigator Brochure.” 12. The appendices were updated to include CRO vendors for Bone Marrow Biopsy Review and Interactive Voice Response System (IVRS). 13. The reference for European Union (EU) Clinical Trial Directive 2001/20/EC was added. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |